EVANGELISTI, CAMILLA
EVANGELISTI, CAMILLA
Istituto di Genetica Molecolare "Luigi Luca Cavalli Sforza"
GSK-3: a multifaceted player in acute leukemias
2021 Martelli, Am; Evangelisti, C; Paganelli, F; Chiarini, F; Mccubrey, Ja
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?
2020 Ratti S; Lonetti A; Follo MY; Paganelli F; Martelli AM; Chiarini F; Evangelisti C.
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.
2020 Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM.
Lamin A and Prelamin a Counteract Migration of Osteosarcoma Cells
2020 Evangelisti C; Paganelli F; Giuntini G; Mattioli E; Cappellini A; Ramazzotti G; Faenza I; Maltarello MC; Martelli AM; Scotlandi K; Chiarini F; Lattanzi G.
Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia
2020 Evangelisti, C; Chiarini, F; Cappellini, A; Paganelli, F; Fini, M; Santi, S; Martelli, Am; Neri, Lm; Evangelisti, C
The role played by wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia
2020 Chiarini F; Paganelli F; Martelli AM; Evangelisti C.
The unfolded protein response: A novel therapeutic target in acute leukemias
2020 Martelli, Am; Paganelli, F; Chiarini, F; Evangelisti, C; Mccubrey, Ja
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.
2019 Chiarini F; Evangelisti C; Lattanzi G; McCubrey JA; Martelli AM.
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia
2019 Paganelli F; Lonetti A; Anselmi L; Martelli AM; Evangelisti C; Chiarini F.
The Cutting Edge: The Role of mTOR Signaling in Laminopathies
2019 Chiarini F.; Evangelisti C.; Cenni V.; Fazio A.; Paganelli F.; Martelli A.M.; Lattanzi G.
Elevated TGF beta 2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes
2018 Bernasconi P; Carboni N; Ricci G; Siciliano G; Politano L; Maggi L; Mongini T; Vercelli L; Rodolico C; Biagini E; Boriani G; Ruggiero L; Santoro L; Schena E; Prencipe S; Evangelisti C; Pegoraro E; Morandi L; Columbaro M; Lanzuolo C; Sabatelli P; Cavalcante P; Cappelletti C; Bonne G; Muchir A; Lattanzi G.
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia
2018 Evangelisti, C; Cappellini, A; Oliveira, M; Fragoso, R; Barata, Jt; Bertaina, A; Locatelli, F; Simioni, C; Neri, Lm; Chiarini, F; Lonetti, A; Buontempo, F; Orsini, E; Pession, A; Manzoli, L; Martelli, Am; Evangelisti, C
Therapeutic targeting of CK2 in acute and chronic leukemias
2018 Buontempo, F; Mccubrey, J A; Orsini, E; Ruzzene, M; Cappellini, A; Lonetti, A; Evangelisti, C; Chiarini, F; Evangelisti, C; Barata, J T; Martelli, A M
Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update
2018 Evangelisti, C; Chiarini, F; Mccubrey, Ja; Martelli, Am
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines
2017 Ultimo, S; Simioni, C; Martelli, Am; Zauli, G; Evangelisti, C; Celeghini, C; Mccubrey, Ja; Marisi, G; Ulivi, P; Capitani, S; Neri, Lm
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting
2016 Chiarini, F; Lonetti, A; Evangelisti, C; Buontempo, F; Orsini, E; Evangelisti, C; Cappellini, A; Neri, Lm; Mccubrey, Ja; Martelli, Am
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
2016 Lonetti, A; Cappellini, A; Bertaina, A; Locatelli, F; Pession, A; Buontempo, F; Evangelisti, C; Evangelisti, C; Orsini, E; Zambonin, L; Neri, Lm; Martelli, Am; Chiarini, F
Potential therapeutic effects of the mtor inhibitors for preventing ageing and progeria-related disorders.
2016 Evangelisti C; Cenni V; Lattanzi G.
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-?B.
2016 Buontempo, F; Orsini, E; Lonetti, A; Cappellini, A; Chiarini, F; Evangelisti, C; Evangelisti, C; Melchionda, F; Pession, A; Bertaina, A; Locatelli, F; Bertacchini, J; Neri, Lm; Mccubrey, Ja; Martelli, Am
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies.
2016 Evangelisti C; Evangelisti C; Buontempo F; Lonetti A; Orsini E; Chiarini F; Barata JT; Pyne S; Pyne NJ; Martelli AM.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| GSK-3: a multifaceted player in acute leukemias | 1-gen-2021 | Martelli, Am; Evangelisti, C; Paganelli, F; Chiarini, F; Mccubrey, Ja | |
| B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? | 1-gen-2020 | Ratti S; Lonetti A; Follo MY; Paganelli F; Martelli AM; Chiarini F; Evangelisti C. | |
| Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. | 1-gen-2020 | Evangelisti C; Chiarini F; Paganelli F; Marmiroli S; Martelli AM. | |
| Lamin A and Prelamin a Counteract Migration of Osteosarcoma Cells | 1-gen-2020 | Evangelisti C; Paganelli F; Giuntini G; Mattioli E; Cappellini A; Ramazzotti G; Faenza I; Maltarello MC; Martelli AM; Scotlandi K; Chiarini F; Lattanzi G. | |
| Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia | 1-gen-2020 | Evangelisti, C; Chiarini, F; Cappellini, A; Paganelli, F; Fini, M; Santi, S; Martelli, Am; Neri, Lm; Evangelisti, C | |
| The role played by wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia | 1-gen-2020 | Chiarini F; Paganelli F; Martelli AM; Evangelisti C. | |
| The unfolded protein response: A novel therapeutic target in acute leukemias | 1-gen-2020 | Martelli, Am; Paganelli, F; Chiarini, F; Evangelisti, C; Mccubrey, Ja | |
| Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. | 1-gen-2019 | Chiarini F; Evangelisti C; Lattanzi G; McCubrey JA; Martelli AM. | |
| New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia | 1-gen-2019 | Paganelli F; Lonetti A; Anselmi L; Martelli AM; Evangelisti C; Chiarini F. | |
| The Cutting Edge: The Role of mTOR Signaling in Laminopathies | 1-gen-2019 | Chiarini F.; Evangelisti C.; Cenni V.; Fazio A.; Paganelli F.; Martelli A.M.; Lattanzi G. | |
| Elevated TGF beta 2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes | 1-gen-2018 | Bernasconi P; Carboni N; Ricci G; Siciliano G; Politano L; Maggi L; Mongini T; Vercelli L; Rodolico C; Biagini E; Boriani G; Ruggiero L; Santoro L; Schena E; Prencipe S; Evangelisti C; Pegoraro E; Morandi L; Columbaro M; Lanzuolo C; Sabatelli P; Cavalcante P; Cappelletti C; Bonne G; Muchir A; Lattanzi G. | |
| Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia | 1-gen-2018 | Evangelisti, C; Cappellini, A; Oliveira, M; Fragoso, R; Barata, Jt; Bertaina, A; Locatelli, F; Simioni, C; Neri, Lm; Chiarini, F; Lonetti, A; Buontempo, F; Orsini, E; Pession, A; Manzoli, L; Martelli, Am; Evangelisti, C | |
| Therapeutic targeting of CK2 in acute and chronic leukemias | 1-gen-2018 | Buontempo, F; Mccubrey, J A; Orsini, E; Ruzzene, M; Cappellini, A; Lonetti, A; Evangelisti, C; Chiarini, F; Evangelisti, C; Barata, J T; Martelli, A M | |
| Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update | 1-gen-2018 | Evangelisti, C; Chiarini, F; Mccubrey, Ja; Martelli, Am | |
| PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines | 1-gen-2017 | Ultimo, S; Simioni, C; Martelli, Am; Zauli, G; Evangelisti, C; Celeghini, C; Mccubrey, Ja; Marisi, G; Ulivi, P; Capitani, S; Neri, Lm | |
| Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting | 1-gen-2016 | Chiarini, F; Lonetti, A; Evangelisti, C; Buontempo, F; Orsini, E; Evangelisti, C; Cappellini, A; Neri, Lm; Mccubrey, Ja; Martelli, Am | |
| Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway | 1-gen-2016 | Lonetti, A; Cappellini, A; Bertaina, A; Locatelli, F; Pession, A; Buontempo, F; Evangelisti, C; Evangelisti, C; Orsini, E; Zambonin, L; Neri, Lm; Martelli, Am; Chiarini, F | |
| Potential therapeutic effects of the mtor inhibitors for preventing ageing and progeria-related disorders. | 1-gen-2016 | Evangelisti C; Cenni V; Lattanzi G. | |
| Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-?B. | 1-gen-2016 | Buontempo, F; Orsini, E; Lonetti, A; Cappellini, A; Chiarini, F; Evangelisti, C; Evangelisti, C; Melchionda, F; Pession, A; Bertaina, A; Locatelli, F; Bertacchini, J; Neri, Lm; Mccubrey, Ja; Martelli, Am | |
| Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. | 1-gen-2016 | Evangelisti C; Evangelisti C; Buontempo F; Lonetti A; Orsini E; Chiarini F; Barata JT; Pyne S; Pyne NJ; Martelli AM. |